MBX Biosciences (MBX) grants stock options to director Ora Pescovitz

Rhea-AI Filing Summary

MBX Biosciences director Ora H. Pescovitz received a grant of stock options, reflecting equity-based compensation rather than an open-market trade. The award covers 12,500 options to buy common stock at an exercise price of $30.91 per share, expiring on June 4, 2036.

According to the terms, the grant will vest in full on the earlier of the one-year anniversary of the grant date or the company’s next annual stockholder meeting, subject to her continued service as a non-employee director. Following this filing, she also holds 24,329 shares of common stock directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Pescovitz Ora H.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	12,500	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock option (right to buy) — 12,500 shares (Direct, null); Common Stock — 24,329 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Stock options granted: 12,500 options Exercise price: $30.91 per share Option expiration: June 4, 2036 +2 more

5 metrics

Stock options granted 12,500 options Grant of stock options to non-employee director

Exercise price $30.91 per share Exercise price of the 12,500 stock options

Option expiration June 4, 2036 Expiration date of the stock option grant

Common shares held 24,329 shares Direct common stock ownership after the reported transactions

Vesting trigger Earlier of one year or next annual meeting Full vesting condition for the stock option grant

Key Terms

Stock option (right to buy), exercise price, expiration date, non-employee director

4 terms

Stock option (right to buy) financial

"Stock option (right to buy)"

exercise price financial

"conversion_or_exercise_price": "30.9100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2036-06-04T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

non-employee director financial

"subject to the non-employee director's continued services to the Company"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pescovitz Ora H.

(Last) (First) (Middle)

C/O MBX BIOSCIENCES, INC.

11711 N. MERIDIAN STREET, SUITE 300

(Street)

CARMEL INDIANA 46032

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MBX Biosciences, Inc. [ MBX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								24,329	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$30.91	06/04/2026		A		12,500		(1)	06/04/2036	Common Stock	12,500	$0	12,500	D

Explanation of Responses:

1. The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company.

	/s/ P. Kent Hawryluk, attorney-in-fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)